Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Physiomics ( (GB:PYC) ) has shared an announcement.
Physiomics has cancelled the general meeting that had been scheduled for 7 April 2026 after revising the terms of its previously announced equity fundraising. The board scrapped the original placing at 0.3 pence per share and instead completed, subject to admission, a revised placing and retail offer at 0.4 pence, rendering the proposed resolutions obsolete and prompting the board to affirm the new structure is in shareholders’ best interests.
Existing proxy appointments for the cancelled meeting are now invalid, and shareholders are advised not to attend the previously designated venue on that date. Stakeholders are told that no immediate action is required in response to the cancellation, underscoring that governance mechanics have been reset to reflect the improved pricing of the revised capital raise.
The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.39 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Spark’s Take on PYC Stock
According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.
To see Spark’s full report on PYC stock, click here.
More about Physiomics
Physiomics plc is a UK-based mathematical modelling, data science and biostatistics specialist focused on supporting the development of new therapeutics and personalised medicine solutions. The company applies computational tools, bespoke models and its proprietary Virtual Tumour technology to help biotech and pharma clients streamline drug development and de-risk decision making across discovery, pre-clinical and clinical stages.
Average Trading Volume: 7,741,479
Technical Sentiment Signal: Sell
Current Market Cap: £1.26M
Learn more about PYC stock on TipRanks’ Stock Analysis page.

